{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:40:08Z","timestamp":1790844008503,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006693","name":"Consortium Dermatological Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.labinv.2024.102209","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T07:31:34Z","timestamp":1734075094000},"page":"102209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Downregulation of MHC-I on Melanoma Cells and Decreased CD8+ T-Cell Infiltration Are Associated With Metastatic Spread and Resistance to Immunotherapy"],"prefix":"10.1016","volume":"105","author":[{"given":"Miriam","family":"Mengoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix O.","family":"Mahlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Gaffal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"T\u00fcting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6954-0633","authenticated-orcid":false,"given":"Andreas D.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6382","key":"10.1016\/j.labinv.2024.102209_bib1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.labinv.2024.102209_bib2","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial","volume":"29","author":"Kirkwood","year":"2023","journal-title":"Nat Med"},{"issue":"10336","key":"10.1016\/j.labinv.2024.102209_bib3","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 tsial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.labinv.2024.102209_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.05.003","article-title":"Adjuvant therapy for stage II melanoma: the need for further studies","volume":"189","author":"Lee","year":"2023","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.labinv.2024.102209_bib5","first-page":"705","article-title":"The histogenesis and biologic behavior of primary human malignant melanomas of the skin","volume":"29","author":"Clark","year":"1969","journal-title":"Cancer Res"},{"issue":"24","key":"10.1016\/j.labinv.2024.102209_bib6","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/jnci\/81.24.1893","article-title":"Model predicting survival in stage I melanoma based on tumor progression","volume":"81","author":"Clark","year":"1989","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.labinv.2024.102209_bib7","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5","article-title":"Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma","volume":"77","author":"Clemente","year":"1996","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.labinv.2024.102209_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol"},{"issue":"3","key":"10.1016\/j.labinv.2024.102209_bib9","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/pcmr.12757","article-title":"Comparison of five different scoring methods in the evaluation of inflammatory infiltration (tumor-infiltrating lymphocytes) in superficial spreading and nodular melanoma","volume":"32","author":"N\u011bmejcov\u00e1","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"issue":"64","key":"10.1016\/j.labinv.2024.102209_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abj8825","article-title":"Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8+ T cell clone size and cytotoxicity","volume":"6","author":"Watson","year":"2021","journal-title":"Sci Immunol"},{"issue":"5","key":"10.1016\/j.labinv.2024.102209_bib11","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.labinv.2024.102209_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.labinv.2024.102209_bib13","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1172\/JCI498","article-title":"Beta2-microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma","volume":"101","author":"Hicklin","year":"1998","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.labinv.2024.102209_bib14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jnci\/88.2.100","article-title":"Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy","volume":"88","author":"Restifo","year":"1996","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"7967","key":"10.1016\/j.labinv.2024.102209_bib15","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41586-023-06199-x","article-title":"CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours","volume":"618","author":"Kruse","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.labinv.2024.102209_bib16","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","article-title":"Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.labinv.2024.102209_bib17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00428-023-03637-z","article-title":"Cutting-edge technology and automation in the pathology laboratory","volume":"484","author":"Munari","year":"2024","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1016\/j.labinv.2024.102209_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1369\/jhc.2010.957191","article-title":"Antigen retrieval immunohistochemistry: review and future prospects in research and diagnosis over two decades","volume":"59","author":"Shi","year":"2011","journal-title":"J\u00a0Histochem Cytochem"},{"issue":"9","key":"10.1016\/j.labinv.2024.102209_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2024.102111","article-title":"Implementation of digital pathology and artificial intelligence in routine pathology practice","volume":"104","author":"Zhang","year":"2024","journal-title":"Lab Invest"},{"issue":"1","key":"10.1016\/j.labinv.2024.102209_bib37","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"issue":"18","key":"10.1016\/j.labinv.2024.102209_bib20","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.labinv.2024.102209_bib21","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.labinv.2024.102209_bib22","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.ajpath.2023.08.013","article-title":"Tumor-infiltrating lymphocyte recognition in primary melanoma by deep learning convolutional neural network","volume":"193","author":"Ugolini","year":"2023","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.labinv.2024.102209_bib23","doi-asserted-by":"crossref","first-page":"5440","DOI":"10.1038\/s41467-019-13043-2","article-title":"An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma","volume":"10","author":"Acs","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.labinv.2024.102209_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104644","article-title":"Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases","volume":"93","author":"Chatziioannou","year":"2023","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.labinv.2024.102209_bib25","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.labinv.2024.102209_bib26","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ijc.30489","article-title":"The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration","volume":"140","author":"Perea","year":"2017","journal-title":"Int J Cancer"},{"issue":"2 Pt 1","key":"10.1016\/j.labinv.2024.102209_bib27","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.498.11.2","article-title":"Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma","volume":"11","author":"Ryschich","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.labinv.2024.102209_bib28","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1158\/1078-0432.CCR-21-3501","article-title":"The challenges of HLA class I loss in cancer immunotherapy: facts and hopes","volume":"28","author":"Aptsiauri","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.labinv.2024.102209_bib29","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/nbt.3344","article-title":"Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes","volume":"33","author":"Shukla","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.labinv.2024.102209_bib30","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.labinv.2024.102209_bib31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","article-title":"An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer","volume":"36","author":"Burr","year":"2019","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.labinv.2024.102209_bib32","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.devcel.2019.06.011","article-title":"DUX4 suppresses MHC class I to promote cancer immune evasion and resistance to checkpoint blockade","volume":"50","author":"Chew","year":"2019","journal-title":"Dev Cell"},{"issue":"7","key":"10.1016\/j.labinv.2024.102209_bib33","doi-asserted-by":"crossref","first-page":"6736","DOI":"10.3390\/ijms24076736","article-title":"Interferons and resistance mechanisms in tumors and pathogen-driven diseases-focus on the major histocompatibility complex (MHC) antigen processing pathway","volume":"24","author":"Massa","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.labinv.2024.102209_bib34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.labinv.2024.102209_bib35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"10.1016\/j.labinv.2024.102209_bib36","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/2326-6066.CIR-19-0229","article-title":"STING signaling in melanoma cells shapes antigenicity and can promote antitumor T-cell activity","volume":"7","author":"Falahat","year":"2019","journal-title":"Cancer Immunol Res"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683724018877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683724018877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T12:25:04Z","timestamp":1742300704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683724018877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0023683724018877"],"URL":"https:\/\/doi.org\/10.1016\/j.labinv.2024.102209","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Downregulation of MHC-I on Melanoma Cells and Decreased CD8+ T-Cell Infiltration Are Associated With Metastatic Spread and Resistance to Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.labinv.2024.102209","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"102209"}}